Osaic Holdings’s Context Therapeutics CNTX Stock Holding History

Osaic Holdings’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.5K	Sell	10,500 -15,000	-59%	-$35K	﹤0.01%	5642
2025 Q4	$37.5K	Hold	25,500	–	–	﹤0.01%	5437
2025 Q3	$24.6K	Buy	25,500 +15,000	+143%	+$12.2K	﹤0.01%	5796
2025 Q2	$6.83K	Buy	10,500 +500	+5%	+$360	﹤0.01%	6371
2025 Q1	$6.1K	Sell	10,000 -500	-5%	-$435	﹤0.01%	6073
2024 Q4	$11K	Buy	10,500 +10,000	+2,000%	+$17.3K	﹤0.01%	5727
2024 Q3	$980	Hold	500	–	–	﹤0.01%	6847
2024 Q2	$1K	Sell	500 -1,000	-67%	-$1.72K	﹤0.01%	6815
2024 Q1	$2.07K	Hold	1,500	–	–	﹤0.01%	6455
2023 Q4	$1.7K	Hold	1,500	–	–	﹤0.01%	6587
2023 Q3	$2.27K	Hold	1,500	–	–	﹤0.01%	6586
2023 Q2	$2.4K	Buy	+1,500	New	+$1.28K	﹤0.01%	6598

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Osaic Holdings's CNTX Position: Q1 2026 in Review

Osaic Holdings reduced its Context Therapeutics (CNTX) stake by 59% in Q1 2026, selling an estimated $35K and leaving 10,500 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5642.

Osaic Holdings first reported a position in CNTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $37.5K in Q4 2025. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Osaic Holdings held 10,500 shares of Context Therapeutics worth $27.5K as of Q1 2026.
Osaic Holdings sold 15,000 Context Therapeutics shares in Q1 2026, an estimated $35K.
Context Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5642 holding.
Osaic Holdings first reported a position in Context Therapeutics in Q2 2023 and has held it in 12 quarters since.
Osaic Holdings's Context Therapeutics position peaked at $37.5K in Q4 2025.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.